{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:48:09Z","timestamp":1794023289112,"version":"4.8.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004320","name":"Philips","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AAA"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AAA"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AAA"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jtho.2019.02.002","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T12:16:00Z","timestamp":1550060160000},"page":"993-1002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors"],"prefix":"10.1016","volume":"14","author":[{"given":"Patrick","family":"Robelin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Hadoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Forestier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Planchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Hervieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Berdelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Scoazec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Jean","family":"Valette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Leboulleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lombard-Bohas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2019.02.002_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2019.02.002_bib2","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.5858\/2009-0583-RAR.1","article-title":"Neuroendocrine tumors of the lung: an update","volume":"134","author":"Rekhtman","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2019.02.002_bib3","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/annonc\/mdv041","article-title":"Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids","volume":"26","author":"Caplin","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2019.02.002_bib4","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.02.002_bib5","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/S1470-2045(17)30681-2","article-title":"Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial","volume":"18","author":"Ferolla","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2019.02.002_bib6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"The frequency of carcinoid syndrome at neuroendocrine tumor diagnosis: a large population-based study using SEER-Medicare data","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2019.02.002_bib7","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1378\/chest.119.6.1647","article-title":"Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature","volume":"119","author":"Fink","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2019.02.002_bib8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2005.04.1202","article-title":"Neuroendocrine neoplasms of the lung: a prognostic spectrum","volume":"24","author":"Asamura","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2019.02.002_bib9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejcts.2006.11.031","article-title":"Typical and atypical carcinoid tumours: analysis of the experience of\u00a0the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung","volume":"31","author":"Garc\u00eda-Yuste","year":"2007","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2019.02.002_bib10","first-page":"335","article-title":"Prognostic factors in typical and atypical pulmonary carcinoids","volume":"17","author":"Ramirez","year":"2017","journal-title":"Ochsner J"},{"issue":"suppl 7","key":"10.1016\/j.jtho.2019.02.002_bib11","doi-asserted-by":"crossref","first-page":"vii120","DOI":"10.1093\/annonc\/mds267","article-title":"Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"\u00d6berg","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2019.02.002_bib12","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/MPA.0b013e3181ec1380","article-title":"NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus)","volume":"39","author":"Phan","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.jtho.2019.02.002_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00259-015-3190-7","article-title":"Long-term results of PRRT in advanced bronchopulmonary carcinoid","volume":"43","author":"Mariniello","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jtho.2019.02.002_bib14","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s00259-015-3262-8","article-title":"Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET","volume":"43","author":"Ianniello","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jtho.2019.02.002_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000354760","article-title":"Effect of temozolomide\u00a0in patients with metastatic bronchial carcinoids","volume":"98","author":"Crona","year":"2013","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.jtho.2019.02.002_bib16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.lungcan.2016.03.018","article-title":"Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors","volume":"96","author":"Walter","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.02.002_bib17","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1010-7940(02)00055-6","article-title":"Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide","volume":"21","author":"Filosso","year":"2002","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2019.02.002_bib18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cllc.2016.11.004","article-title":"Outcome analysis of first-line somatostatin analog treatment in metastatic pulmonary neuroendocrine tumors and prognostic significance\u00a0of 18FDG-PET\/CT","volume":"18","author":"Bongiovanni","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2019.02.002_bib19","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1023\/A:1012569909313","article-title":"Experience in treatment of metastatic pulmonary carcinoid tumors","volume":"12","author":"Granberg","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2019.02.002_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.lungcan.2014.08.012","article-title":"Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors","volume":"86","author":"Chong","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.02.002_bib21","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2019.02.002_bib22","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2019.02.002_bib23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2019.02.002_bib24","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/cas.13427","article-title":"Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis","volume":"109","author":"Fazio","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtho.2019.02.002_bib25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.thorsurg.2014.04.002","article-title":"Clinical presentation and evaluation of neuroendocrine tumors of the lung","volume":"24","author":"Detterbeck","year":"2014","journal-title":"Thorac Surg Clin"},{"key":"10.1016\/j.jtho.2019.02.002_bib26","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/JTO.0b013e3181861d7b","article-title":"Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007","volume":"3","author":"Lim","year":"2008","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.02.002_bib27","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.jtho.2018.06.023","article-title":"Carcinoid heart disease in patients with bronchopulmonary carcinoid","volume":"13","author":"De Jesus","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.02.002_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000287255","article-title":"ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors","volume":"91","author":"Kos-Kud\u0142a","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.jtho.2019.02.002_bib29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1530\/ERC-16-0464","article-title":"Treatment of metastatic pancreatic neuroendocrine tumors: relevance of ENETS 2016 guidelines","volume":"24","author":"Foulfoin","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.jtho.2019.02.002_bib30","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2019.02.002_bib31","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1677\/ERC-08-0301","article-title":"Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma","volume":"16","author":"Durante","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.jtho.2019.02.002_bib32","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-2265.2004.02030.x","article-title":"Interest of chromogranin A for diagnosis and follow-up of endocrine tumours","volume":"60","author":"Nehar","year":"2004","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.jtho.2019.02.002_bib33","unstructured":"Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). WHO Classification of Tumours of the Digestive System. Geneva, Switzerland; World Health Organization, 2010."},{"key":"10.1016\/j.jtho.2019.02.002_bib34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/JTO.0000000000000092","article-title":"Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice","volume":"9","author":"Pelosi","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.02.002_bib35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000335597","article-title":"ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary","volume":"95","author":"Pavel","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.jtho.2019.02.002_bib36","first-page":"259","article-title":"Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids","volume":"75","author":"Sullivan","year":"2017","journal-title":"Eur J Cancer 1990"},{"key":"10.1016\/j.jtho.2019.02.002_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1054\/bjoc.2000.1164","article-title":"Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent","volume":"83","author":"Pujol","year":"2000","journal-title":"Br J Cancer"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2019.02.002_bib39","article-title":"A\u00a0randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: a trial of the ECOG-ACRIN Cancer Research\u00a0Group (E2211)","volume":"36","author":"Kunz","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2019.02.002_bib40","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1677\/ERC-09-0104","article-title":"Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710","volume":"16","author":"Dahan","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.jtho.2019.02.002_bib41","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1378\/chest.12-1108","article-title":"Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study","volume":"143","author":"Fazio","year":"2013","journal-title":"Chest"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086419301030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086419301030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:40:01Z","timestamp":1761561601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086419301030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1556086419301030"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2019.02.002","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2019.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}